エピソード

  • ANCA Vasculitis: From Pathophysiology to Precision Treatment in the Hospitalized Patient

    ANCA Vasculitis: From Pathophysiology to Precision Treatment in the Hospitalized Patient
    2026/04/10

    In this episode of Hospital Medicine Unplugged, we break down ANCA-associated vasculitis (AAV)—granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA)—focusing on modern epidemiology, complement-driven pathophysiology, ANCA serotypes, and the rapidly evolving treatment landscape.

    We start with epidemiology clinicians should recognize. The global incidence of AAV is ~17 per million person-years, with a prevalence near 198 per million. In the United States, incidence is roughly 3.3 per 100,000, with a prevalence of ~42 per 100,000. Subtype incidence varies: GPA (~9–15/million), MPA (~6/million), and EGPA (~2/million). The mean age at diagnosis is about 61, and rates have increased over the past decades due to greater recognition and widespread ANCA testing.

    Next we unpack the pathophysiology that changed therapy. Complement activation—particularly the alternative pathway—plays a central role. C5a drives neutrophil activation and recruitment, creating an inflammatory amplification loop. Low C3 levels correlate with more aggressive disease and worse renal outcomes. This mechanistic insight led to avacopan, an oral C5a receptor antagonist that provides a glucocorticoid-sparing approach to treatment.

    We then highlight the importance of ANCA serotype classification. Patients are increasingly categorized by PR3-ANCA vs MPO-ANCA, not just clinical phenotype. • PR3-ANCA disease is more often GPA, with ENT involvement, pulmonary nodules, and higher relapse risk. • MPO-ANCA disease more often presents as MPA, with renal-limited disease, interstitial lung disease, and higher mortality.

    We also review EGPA as a distinct entity. Only ~40% of patients are ANCA-positive. Two clinical subsets exist: • ANCA-positive EGPA → vasculitic manifestations such as glomerulonephritis and neuropathy • ANCA-negative EGPA → eosinophilic disease with pulmonary infiltrates and cardiomyopathy Asthma is a defining feature, and cardiac involvement is a major driver of mortality.

    Diagnosis relies on modern ANCA testing and organ evaluation. PR3- and MPO-specific immunoassays are now the preferred screening tests, with ~90–95% sensitivity for active GPA/MPA and >95% specificity. Renal disease occurs in 70–80% of GPA/MPA, typically as pauci-immune necrotizing crescentic glomerulonephritis, while pulmonary disease ranges from nodules and cavitation (PR3) to interstitial lung disease (MPO) and diffuse alveolar hemorrhage.

    Management has evolved dramatically. First-line induction therapy combines glucocorticoids with rituximab or cyclophosphamide, with rituximab preferred for most patients—especially PR3-ANCA or relapsing disease. Reduced-dose steroid regimens are now recommended after trials like PEXIVAS, which showed lower infection risk without worse renal outcomes.

    We also cover key modern therapies. • Avacopan, a C5a receptor antagonist, improves sustained remission and kidney recovery while reducing steroid exposure. • Plasma exchange remains controversial after the PEXIVAS trial, but may still be considered in severe kidney failure, dialysis-dependent disease, or diffuse alveolar hemorrhage.

    For maintenance therapy, rituximab is now the preferred agent, outperforming azathioprine in major trials such as MAINRITSAN and RITAZAREM. Maintenance typically continues 2–4 years, especially in PR3-ANCA patients with high relapse risk.

    We finish with EGPA-specific treatment advances. IL-5 pathway inhibitors have transformed care, including mepolizumab and the newer benralizumab, which improve remission rates and allow significant glucocorticoid reduction.

    The bottom line: AAV management has shifted toward precision medicine—ANCA serotype classification, complement-targeted therapy, steroid-sparing strategies, and biologic maintenance treatments—dramatically improving survival and long-term outcomes.
    続きを読む 一部表示
    32 分
  • Clinical Management and Metabolism of Fat-Soluble Vitamins in the Hospitalized Patient

    Clinical Management and Metabolism of Fat-Soluble Vitamins in the Hospitalized Patient
    2026/04/08
    In this episode of Hospital Medicine Unplugged, we sprint through fat-soluble vitamins—A, D, E, and K—focusing on how they’re absorbed, why deficiencies happen, and the clinical syndromes hospitalists must recognize early. From intestinal transporters to neurologic deficits and neonatal bleeding, we connect physiology to bedside decision-making. We start with absorption mechanics, which are more complex than simple passive diffusion. Modern research shows specific intestinal transporters—SR-BI, CD36, NPC1L1, and ABCA1—facilitate uptake of vitamins D, E, and K. Interestingly, vitamin A appears to lack a dedicated membrane transporter for dietary absorption. Absorption is also competitive: vitamins D, E, and K compete with one another, while vitamin A can suppress absorption of other fat-soluble vitamins without being affected itself. This interaction becomes clinically relevant in patients taking high-dose supplements. Next we tackle vitamin A—vision, epithelial integrity, and immune defense. Deficiency follows a classic progression: • Night blindness (earliest symptom) • Xerophthalmia • Bitot spots • Irreversible corneal damage and blindness Vitamin A also regulates epithelial differentiation and T-cell immune function, so deficiency increases susceptibility to infection. Even in high-income settings, restrictive diets or selective eating can lead to severe deficiency and permanent ocular injury. Toxicity is equally important. Chronic hypervitaminosis A causes: • Elevated intracranial pressure (headache, vomiting, papilledema, bulging fontanelle in infants) • Hepatotoxicity • Bone abnormalities from vitamin D receptor antagonism • Teratogenic effects Sustained doses around 50,000 IU daily for >18 months can produce chronic toxicity. We then shift to vitamin D—arguably the most clinically debated fat-soluble vitamin. Vitamin D metabolism follows a three-step pathway: UVB exposure converts 7-dehydrocholesterol in skin to vitamin D3 Hepatic conversion to 25-hydroxyvitamin D (calcidiol) Renal activation to calcitriol (1,25-dihydroxyvitamin D) This active hormone regulates calcium and phosphate homeostasis through tight feedback with parathyroid hormone. Deficiency is widespread—over one billion people globally. Classic consequences include rickets in children and osteomalacia or osteoporosis in adults, but deficiency also contributes to proximal muscle weakness, increasing fall and fracture risk. Vitamin D receptors are expressed throughout the body, and observational data link deficiency with cardiovascular disease, autoimmune disease, diabetes, multiple sclerosis, and cancer, although randomized trials show mixed results for extraskeletal benefits. A key clinical debate remains optimal levels. Many experts advocate serum 25-hydroxyvitamin D concentrations above 40–50 ng/mL, often requiring supplementation beyond traditional recommendations. Next up: vitamin E—the neurologic protector. Deficiency primarily manifests with neurologic disease, including: • Peripheral neuropathy • Cerebellar and sensory ataxia • Posterior column dysfunction • Hyporeflexia • Oculomotor abnormalities such as impaired upward gaze Severe cases can progress to blindness and dementia. In cholestatic patients, interpretation requires nuance. Vitamin E levels may appear falsely normal due to hyperlipidemia, so clinicians should measure the vitamin E–to–total lipid ratio instead. Another diagnostic clue is red blood cell acanthocytosis on blood smear. Toxicity is uncommon but high-dose vitamin E increases bleeding risk, particularly in patients taking anticoagulants. We close with vitamin K—the coagulation vitamin with expanding roles in vascular biology. Vitamin K enables γ-carboxylation of clotting factors II, VII, IX, and X and anticoagulant proteins C and S. Deficiency produces functional clotting factor impairment and bleeding once levels fall below ~30 U/dL. In neonates, vitamin K deficiency bleeding (VKDB) occurs in three forms: • Early (<24 hours) – linked to maternal medications • Classic (2–7 days) • Late (1–3 months) – the most dangerous, with >50% presenting with intracranial hemorrhage Routine intramuscular vitamin K prophylaxis at birth prevents nearly all cases of late VKDB. Beyond coagulation, vitamin K activates matrix Gla protein, a powerful inhibitor of vascular calcification, and osteocalcin, which supports bone metabolism. We also spotlight high-risk populations for fat-soluble vitamin deficiency, including patients with: • Cholestatic liver disease • Chronic pancreatitis and pancreatic insufficiency • Inflammatory bowel disease or celiac disease • Cystic fibrosis • Bariatric surgery • Genetic lipid disorders such as abetalipoproteinemia or α-TTP deficiency Certain medications impair absorption as well—orlistat, cholestyramine, and long-term antibiotics. Finally, we review laboratory assessment strategies that actually work. • ...
    続きを読む 一部表示
    29 分
  • Thalassemias: Genetics, Pathophysiology, and Clinical Manifestations in the Hospitalized Patient

    Thalassemias: Genetics, Pathophysiology, and Clinical Manifestations in the Hospitalized Patient
    2026/04/06

    In this episode of Hospital Medicine Unplugged, we sprint through thalassemia—an inherited hemoglobinopathy defined by reduced or absent globin chain production, ineffective erythropoiesis, and chronic anemia. We break down the genetics, pathophysiology, clinical spectrum, and why this disorder remains the most common monogenic disease worldwide.

    We start with the big picture. About 5% of the global population carries an α-thalassemia allele and 1.5% carries a β-thalassemia allele, with roughly 1.3 million people living with disease and ~40,000 affected infants born annually. The condition clusters across malaria-endemic regions—from sub-Saharan Africa and the Mediterranean to the Middle East, South Asia, and Southeast Asia—because the carrier state provides partial protection against malaria. Migration has increasingly brought thalassemia to North America and Europe, expanding its global clinical impact.

    Next, we revisit normal hemoglobin physiology. Adult hemoglobin (HbA) is α₂β₂, with smaller fractions of HbA₂ (α₂δ₂) and HbF (α₂γ₂). During infancy, the body transitions from fetal hemoglobin to adult hemoglobin as γ-globin declines and β-globin production increases, regulated by transcription factors such as BCL11A and KLF1. Balanced α- and β-chain production is essential—when the balance breaks, unpaired globin chains accumulate, precipitate, and damage developing red cells, driving ineffective erythropoiesis.

    We then dive into the genetic architecture. α-globin genes (HBA1, HBA2) sit on chromosome 16 with four total copies, while the β-globin gene (HBB) lies on chromosome 11 with two total copies.

    • α-thalassemia is usually caused by gene deletions affecting HBA1 or HBA2. • β-thalassemia typically results from point mutations affecting transcription, RNA splicing, or translation.

    Mutations are classified as: • β⁰ mutations: no β-globin production • β⁺ mutations: reduced β-globin synthesis

    Severity depends on genotype, but genetic modifiers matter—coinherited α-thalassemia, increased HbF production, or α-globin gene duplications can significantly alter disease expression.

    Next, we map the clinical classification.

    Alpha thalassemia spectrum: • Silent carrier: one gene affected, usually asymptomatic • α-thalassemia trait: two genes affected, mild microcytic anemia • Hemoglobin H disease: three genes affected → moderate-severe hemolytic anemia with β₄ tetramers • Hb Bart’s hydrops fetalis: four genes deleted → incompatible with life

    Beta thalassemia spectrum: • β-thalassemia trait: mild microcytic anemia with elevated HbA₂ (>3.5%) • β-thalassemia intermedia: moderate anemia with variable transfusion needs • β-thalassemia major (Cooley anemia): severe disease presenting in infancy requiring lifelong transfusions

    Compound disorders add complexity, including HbE-β thalassemia and sickle-β thalassemia, where severity depends on the interacting mutations.

    Then we unpack the pathophysiology driving complications.

    Excess unpaired globin chains cause oxidative damage and premature death of erythroid precursors, leading to: • Ineffective erythropoiesis with massive marrow expansion • Hemolysis from fragile red cells • Extramedullary hematopoiesis in liver and spleen

    Chronic erythropoietin stimulation leads to skeletal deformities—frontal bossing, maxillary hypertrophy, and long-bone abnormalities.

    Iron overload develops through two major pathways: • Transfusion iron loading (each unit adds ~200–250 mg of iron) • Increased intestinal absorption from suppressed hepcidin due to ineffective erythropoiesis

    The downstream damage is systemic: cardiomyopathy, arrhythmias, liver fibrosis and cirrhosis, endocrine failure (growth delay, diabetes, hypothyroidism, hypoparathyroidism), osteoporosis, and thrombosis risk.

    We close with the clinical spectrum.

    • Trait: usually asymptomatic with incidental microcytosis • Intermedia: moderate anemia (Hb ~7–10 g/dL), skeletal changes, gallstones, pulmonary hypertension, extramedullary masses • Major: early infancy presentation with severe anemia, failure to thrive, hepatosplenomegaly, and the classic “chipmunk facies” from marrow expansion

    Bottom line: thalassemia is a disorder of globin chain imbalance leading to ineffective erythropoiesis, hemolysis, marrow expansion, and iron overload. Understanding the genetics, modifiers, and pathophysiology is essential to predicting severity, guiding transfusion strategies, and preventing the devastating end-organ complications of chronic iron toxicity.
    続きを読む 一部表示
    36 分
  • Clinical Guide to Axial Spondyloarthritis and Ankylosing Spondylitis

    Clinical Guide to Axial Spondyloarthritis and Ankylosing Spondylitis
    2026/04/03
    In this episode of Hospital Medicine Unplugged, we sprint through ankylosing spondylitis and axial spondyloarthritis—recognize inflammatory back pain early, understand the disease spectrum from non-radiographic to radiographic disease, and treat aggressively to prevent structural damage and disability. We begin with the modern concept of axial spondyloarthritis (axSpA), which represents a disease spectrum rather than a single condition. At one end is non-radiographic axial spondyloarthritis (nr-axSpA)—patients with typical symptoms but without definitive radiographic sacroiliitis. At the other end is radiographic axial spondyloarthritis (r-axSpA), historically known as ankylosing spondylitis, where structural changes in the sacroiliac joints are visible on X-ray. Globally, axial spondyloarthritis affects roughly 0.3% to 1.4% of the population, with about 1% prevalence in the United States. Disease onset typically occurs early in life—more than 80% of patients develop symptoms before age 30. Radiographic disease is more common in men, while non-radiographic disease occurs equally in men and women. A major challenge in this condition is diagnostic delay, which averages nearly seven years from symptom onset. This delay contributes to progressive inflammation, structural damage, and functional impairment before effective therapy is started. The pathogenesis of axial spondyloarthritis involves a combination of genetic susceptibility, immune dysregulation, and environmental triggers. The strongest genetic risk factor is HLA-B27, present in 80–90% of patients with ankylosing spondylitis. Several mechanisms have been proposed to explain how HLA-B27 contributes to disease: • Presentation of arthritogenic peptides to CD8+ T cells • Formation of HLA-B27 dimers, which activate innate immune receptors • Misfolding of HLA-B27 proteins, triggering an unfolded protein response and increased cytokine signaling At the center of the inflammatory cascade lies the IL-23 / IL-17 axis, which drives activation of Th17 cells and production of pro-inflammatory cytokines including IL-17 and TNF-α. Mechanical stress at the entheses—the sites where ligaments and tendons attach to bone—triggers inflammation, making enthesitis the hallmark pathological process. Chronic inflammation eventually stimulates pathologic new bone formation, producing syndesmophytes and spinal ankylosis. Clinically, the hallmark symptom is inflammatory back pain, present in more than 80% of patients. Key features include: • Onset before age 45 years • Gradual onset • Morning stiffness lasting more than 30 minutes • Improvement with exercise • No improvement with rest Extra-articular manifestations are common and often provide diagnostic clues. The most frequent is acute anterior uveitis, occurring in 25–30% of patients. Episodes typically present with sudden eye pain, redness, photophobia, and blurred vision. Other associated conditions include: • Inflammatory bowel disease (5–10%) • Psoriasis (about 10%) • Cardiovascular involvement, including aortic regurgitation and conduction abnormalities • Pulmonary restriction due to chest wall rigidity Because early disease may not show radiographic damage, classification relies on modern criteria. The Modified New York Criteria require definite radiographic sacroiliitis and therefore identify only advanced disease. In contrast, the ASAS classification criteria for axial spondyloarthritis allow earlier diagnosis. These criteria apply to patients with chronic back pain lasting ≥3 months with onset before age 45 and include two diagnostic pathways: • Imaging arm: sacroiliitis on MRI or radiograph plus ≥1 SpA feature • Clinical arm: HLA-B27 positivity plus ≥2 SpA features These criteria have approximately 83% sensitivity and 84% specificity, enabling detection of earlier disease stages. Monitoring disease activity is critical to guide treatment decisions. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred measure because it incorporates both patient-reported symptoms and inflammatory markers such as CRP. ASDAS categories include: • Inactive disease: <1.3 • Low activity: 1.3–2.1 • High activity: 2.1–3.5 • Very high activity: >3.5 Management begins with non-pharmacologic therapy, which remains foundational for all patients. This includes structured exercise programs, physical therapy, posture training, and smoking cessation, as smoking is associated with worse radiographic progression and poorer treatment response. First-line pharmacologic therapy is NSAIDs, which reduce pain and inflammation. Continuous therapy may be more effective than intermittent use, although fewer than one quarter of patients achieve complete symptom control with NSAIDs alone. For patients with persistent disease activity, biologic therapy is the next step. TNF inhibitors were the first biologics proven effective, producing ASAS20 response rates of roughly 60% ...
    続きを読む 一部表示
    22 分
  • Prosthetic Heart Valve Selection and Clinical Management Guide for the Hospitalist

    Prosthetic Heart Valve Selection and Clinical Management Guide for the Hospitalist
    2026/04/01
    In this episode of Hospital Medicine Unplugged, we sprint through prosthetic heart valves—how to choose between mechanical and bioprosthetic valves, manage anticoagulation safely, recognize complications, and navigate the expanding role of transcatheter valve replacement. We begin with the two major categories of prosthetic valves: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves are constructed from durable materials such as pyrolytic carbon and are designed to last decades, but their thrombogenic surface requires lifelong anticoagulation with a vitamin K antagonist. Anticoagulation targets depend on valve position and risk factors. • Mechanical aortic valve: target INR 2.5 • Mechanical mitral valve or high-risk aortic valve: target INR 3.0 In most patients, low-dose aspirin (75–100 mg daily) is added to vitamin K antagonist therapy to further reduce thromboembolic risk. Bioprosthetic valves, in contrast, are made from porcine valves or bovine pericardium. These valves are less thrombogenic, which allows for short-term anticoagulation (typically 3–6 months) after implantation followed by lifelong antiplatelet therapy with aspirin. The trade-off is durability—structural valve degeneration (SVD) eventually occurs due to calcification, fibrosis, or leaflet tearing. Choosing between valve types requires balancing durability versus anticoagulation risk. Mechanical valves generally offer better long-term durability, while bioprosthetic valves avoid lifelong anticoagulation but may require future reoperation. Age is one of the most important factors in valve selection. Evidence from large observational studies demonstrates that mechanical valves provide survival advantages in younger patients, particularly: • Aortic valve replacement: survival benefit up to about age 55 • Mitral valve replacement: survival benefit up to about age 70 Current ACC/AHA guidelines generally recommend: • Mechanical valves: younger patients (<50 years for aortic position, <65 years for mitral) • Bioprosthetic valves: older patients or those with contraindications to long-term anticoagulation The treatment landscape has changed dramatically with the development of transcatheter aortic valve replacement (TAVR). Initially reserved for patients with prohibitive surgical risk, TAVR is now widely used across risk groups. Landmark trials such as PARTNER 3 demonstrated that in low-risk patients with severe aortic stenosis, TAVR produced outcomes comparable to surgical valve replacement at five years. TAVR offers advantages including lower rates of atrial fibrillation and bleeding, though it carries higher risks of paravalvular regurgitation and pacemaker implantation. Guidelines now recommend: • TAVR as a Class I option for patients who are inoperable or high surgical risk • Either TAVR or surgical replacement for patients aged 65–80 years, depending on anatomy and patient factors Anticoagulation management remains one of the most critical aspects of prosthetic valve care. Direct oral anticoagulants (DOACs are contraindicated in mechanical valves). The RE-ALIGN trial showed increased thromboembolic and bleeding complications with dabigatran compared with warfarin, leading to early termination of the study. More recently, the PROACT Xa trial evaluating apixaban in patients with On-X mechanical valves also demonstrated excess thromboembolic events. For bioprosthetic valves, however, DOACs may be used in patients who develop atrial fibrillation, although long-term data remain limited. Despite technological advances, prosthetic valves carry important complications. One of the most serious is prosthetic valve endocarditis (PVE), which is associated with high mortality. Management requires prolonged intravenous antibiotics, typically for at least six weeks, and surgery may be required for heart failure, uncontrolled infection, or large vegetations. Another major complication is prosthetic valve thrombosis, particularly with mechanical valves. Management depends on clinical severity and thrombus size. Options include urgent surgery or low-dose, slow-infusion fibrinolysis, with modern thrombolytic protocols achieving over 90% success rates and low complication rates. A subtler but clinically important issue is prosthesis–patient mismatch (PPM). This occurs when the effective orifice area of the prosthetic valve is too small relative to the patient’s body surface area, creating persistent obstruction despite valve replacement. Severe PPM is defined as indexed effective orifice area <0.65 cm²/m² and is associated with higher mortality, reduced left ventricular mass regression, and worse heart failure outcomes. Certain populations require special consideration. Pregnancy with mechanical valves carries substantial maternal and fetal risk due to the competing challenges of anticoagulation and thrombosis prevention. Warfarin provides the most reliable valve protection but carries risk of embryopathy ...
    続きを読む 一部表示
    35 分
  • Asbestosis: Pathogenesis, Clinical Diagnosis, and Management Strategies in the Hospitalized Patient

    Asbestosis: Pathogenesis, Clinical Diagnosis, and Management Strategies in the Hospitalized Patient
    2026/03/30
    In this episode of Hospital Medicine Unplugged, we sprint through asbestosis—understand how inhaled fibers trigger progressive pulmonary fibrosis, recognize key radiographic features, and manage patients with attention to malignancy risk and progressive fibrotic disease. We start with pathophysiology, where the story begins decades before symptoms appear. After inhalation, asbestos fibers deposit in the distal airways and alveoli. Alveolar macrophages attempt to engulf these fibers, but many fibers are too long to be fully internalized—triggering “frustrated phagocytosis.” This leads to persistent macrophage activation and release of inflammatory mediators including TNF-α, IL-1, and TGF-β. At the same time, reactive oxygen species form both from macrophage activation and from iron on the fiber surface, amplifying oxidative injury. A key early event is alveolar epithelial cell apoptosis, driven by mitochondrial injury, p53-mediated pathways, and endoplasmic reticulum stress. Loss of epithelial integrity and chronic inflammation stimulate fibroblast activation and collagen deposition, ultimately producing the progressive interstitial fibrosis that defines asbestosis. Not all asbestos fibers carry the same risk. Amphibole fibers—particularly crocidolite and amosite—are far more fibrogenic and carcinogenic than chrysotile fibers. Their needle-like shape, durability, and resistance to biological clearance allow them to persist in lung tissue for decades. Fiber dimensions matter: long fibers (>10–20 μm) and extremely thin fibers (<0.25 μm) pose the highest disease risk because they reach distal lung regions and resist macrophage clearance. One of the defining features of asbestos disease is extraordinary latency. Clinical asbestosis usually develops 20–40 years after the first exposure, with peak disease occurrence around 40–45 years after exposure begins. Lung cancer tends to occur earlier, typically 30–35 years after exposure. Disease progression varies—some patients remain stable while others develop progressive fibrotic lung disease with significant annual declines in FVC, particularly those with fibrotic patterns on HRCT. Diagnosis relies on a combination of exposure history, latency, imaging, and pulmonary function testing. According to consensus guidelines, the diagnosis requires: • Documented asbestos exposure • Appropriate latency interval • Radiographic evidence of interstitial fibrosis • Restrictive lung disease with reduced DLCO While chest X-ray can detect classic small irregular opacities, high-resolution CT is far more sensitive. Key HRCT findings include: • Subpleural curvilinear lines (one of the most specific findings) • Intralobular and interlobular septal thickening • Parenchymal bands • Honeycombing in advanced disease Importantly, most patients with asbestosis also show benign pleural abnormalities, such as pleural plaques or diaphragmatic pleural thickening, which strongly support asbestos exposure. Unfortunately, no disease-modifying therapies are currently approved specifically for asbestosis. Management traditionally focuses on supportive care, including: • Smoking cessation • Vaccination against influenza and pneumococcus • Pulmonary rehabilitation • Oxygen therapy for hypoxemia However, the treatment landscape is evolving. Because asbestosis can behave like other progressive fibrosing interstitial lung diseases, antifibrotic therapies are increasingly considered for patients with progressive disease. Nintedanib, approved for progressive fibrosing ILD, may slow lung function decline in patients with progressive asbestosis. Early studies of pirfenidone suggest acceptable safety and potential benefit, though definitive evidence remains limited. Another critical dimension of asbestos exposure is malignancy risk. Asbestos causes two to six times more lung cancers than mesotheliomas, making asbestos-related lung cancer a major public health burden. The interaction with smoking is particularly dangerous: asbestos and smoking have a synergistic effect on lung cancer risk. In exposed workers, the combined effect can increase lung cancer mortality more than 30-fold. Importantly, asbestos exposure increases lung cancer risk even in nonsmokers, but smoking cessation dramatically reduces risk over time. Within 10 years of quitting, lung cancer mortality drops significantly, and after 30 years, risk approaches that of never-smokers. For malignant mesothelioma, amphibole fibers again carry the greatest risk. Crocidolite exposure has the highest potency, and mesothelioma risk continues to rise 40–50 years after initial exposure. Because treatment options for mesothelioma remain limited, prevention and early detection are essential. The most effective intervention is elimination of exposure, enforced through occupational safety regulations, air monitoring, and protective equipment. For individuals with significant asbestos exposure, low-dose CT ...
    続きを読む 一部表示
    30 分
  • A Comprehensive Clinical Guide to Glomerulonephritis for the Hospitalist

    A Comprehensive Clinical Guide to Glomerulonephritis for the Hospitalist
    2026/03/27
    In this episode of Hospital Medicine Unplugged, we sprint through glomerulonephritis—recognize the nephritic syndrome, decode complement patterns and immunofluorescence clues, and manage diseases ranging from self-limited post-infectious GN to rapidly progressive crescentic disease. We start with the clinical syndrome of glomerulonephritis, defined by glomerular inflammation producing hematuria, hypertension, edema, and reduced kidney function. The classic picture is nephritic syndrome—tea- or cola-colored urine, oliguria, periorbital edema, and elevated blood pressure. At the microscopic level, RBC casts are the pathognomonic finding, proving that bleeding originates from the glomerulus rather than the urinary tract. Understanding disease requires revisiting the glomerular filtration barrier, composed of three layers: fenestrated endothelium, the glomerular basement membrane (GBM), and podocytes connected by slit diaphragms. This barrier normally filters plasma while retaining proteins. Podocytes are terminally differentiated and poorly regenerative, making them particularly vulnerable to immune-mediated injury. The core pathophysiology of GN is immune-mediated inflammation. Antibodies, immune complexes, and complement activation trigger inflammatory cascades within the glomerulus. This leads to endocapillary proliferation, mesangial expansion, and leukocyte infiltration, narrowing capillary lumens and lowering GFR. Capillary wall damage allows red blood cells to leak into urine, while the sudden decline in filtration drives sodium and water retention, producing hypertension and edema. Modern classification emphasizes pathogenesis rather than morphology, and most GN falls into five categories: • Immune-complex GN – granular immunoglobulin deposition (post-infectious GN, IgA nephropathy, lupus nephritis, MPGN) • Pauci-immune GN – minimal immune deposition, typically ANCA-associated vasculitis • Anti-GBM disease – linear IgG staining along the basement membrane • Monoclonal immunoglobulin GN – related to plasma cell disorders • C3 glomerulopathy – dominant complement deposition from alternative pathway dysregulation Epidemiology varies by disease. Post-streptococcal GN primarily affects children aged 2–10 years, particularly in developing regions. In contrast, IgA nephropathy is the most common primary glomerular disease worldwide and typically presents in young adults. Interestingly, epidemiology has shifted: childhood PSGN is declining, while adult infection-related GN—often associated with staphylococcal infections—is increasing. Clinical presentation depends on the underlying disease. Post-streptococcal GN typically occurs 1–12 weeks after a streptococcal infection, producing abrupt edema, hypertension, and hematuria. IgA nephropathy, in contrast, often presents with synpharyngitic hematuria—visible hematuria occurring simultaneously with an upper respiratory infection. The urinalysis is the diagnostic cornerstone. Key findings include dysmorphic red blood cells, RBC casts, and mild-to-moderate proteinuria. Complement levels help narrow the differential: • Low C3 and low C4: lupus nephritis, cryoglobulinemia, immune-complex MPGN • Low C3 with normal C4: post-infectious GN or C3 glomerulopathy • Normal complement: IgA nephropathy, ANCA-associated GN, anti-GBM disease A crucial teaching point: C3 should normalize within 6–8 weeks in post-streptococcal GN. Persistent hypocomplementemia suggests another diagnosis, such as lupus nephritis or MPGN. Additional testing includes ASO titers and anti-DNase B antibodies for streptococcal infection, autoimmune markers such as ANA and ANCA, and viral testing for hepatitis B, hepatitis C, and HIV. Imaging plays a limited role. Renal ultrasound typically shows normal or enlarged kidneys in acute GN, helping distinguish acute inflammatory disease from chronic kidney disease. When the diagnosis remains unclear—or when disease is severe—a kidney biopsy is essential. Histology reveals characteristic patterns: • Post-infectious GN: diffuse endocapillary proliferation with neutrophils • Crescents: severe injury indicating rapidly progressive GN • Electron microscopy: classic subepithelial “hump-shaped” deposits in post-infectious disease Immunofluorescence patterns guide classification: • Granular deposition: immune-complex GN • Linear IgG: anti-GBM disease • Pauci-immune: ANCA vasculitis • C3-dominant: C3 glomerulopathy Management begins with supportive care for all patients. Key interventions include: • Blood pressure control, ideally ≤120/70 mmHg with ACE inhibitors or ARBs • Sodium restriction (<2 g/day) • Diuretics for volume overload • Fluid restriction when necessary Treatment then becomes etiology-specific. For post-infectious GN, therapy is largely supportive because the disease usually resolves spontaneously. Edema typically improves within 1–2 weeks, and renal function normalizes ...
    続きを読む 一部表示
    36 分
  • Modern Clinical Management of Thyroid Carcinoma and the Hospitalist's Role in Coordination

    Modern Clinical Management of Thyroid Carcinoma and the Hospitalist's Role in Coordination
    2026/03/25
    In this episode of Hospital Medicine Unplugged, we sprint through thyroid cancer—understand the epidemiologic paradox of rising incidence but stable mortality, stage disease using modern AJCC criteria, apply ATA recurrence risk stratification, and tailor therapy from surgery and radioiodine to targeted molecular treatments. We start with the epidemiology of thyroid carcinoma, the most common endocrine malignancy and the ninth most common cancer worldwide. In 2022 alone, there were roughly 821,000 new cases and 47,500 deaths globally. The disease shows a strong female predominance—about three quarters of cases occur in women, and the median age at diagnosis is in the early 50s. Notably, thyroid cancer is also the most common malignancy among adolescents and young adults aged 16–33 years. One of the most striking trends is the dramatic rise in incidence over the past four decades. Global age-standardized incidence increased substantially from about 2.1 per 100,000 in 1990 to over 3.1 per 100,000 in 2017, with extremely high rates reported in countries such as South Korea, Cyprus, Ecuador, China, and Turkey. Yet mortality has remained remarkably stable at roughly 0.5 per 100,000, suggesting that much of the increase reflects overdiagnosis rather than a true surge in aggressive disease. The driver behind this phenomenon is increased detection of small papillary thyroid cancers, often discovered incidentally during thyroid ultrasonography or cross-sectional imaging. Some studies estimate that more than 75% of thyroid cancers globally may represent overdiagnosis, particularly in high-income countries where imaging is widespread. Encouragingly, incidence rates have begun to plateau or decline in some regions following guideline changes discouraging unnecessary biopsy and treatment of very small nodules. Next, we turn to staging, which guides prognosis and management. The AJCC 8th edition TNM staging system introduced an important shift by raising the prognostic age cutoff from 45 to 55 years. This reflects the excellent survival outcomes seen in younger patients. For patients younger than 55 years, staging is remarkably simple: • Stage I: any tumor size, any lymph node status, no distant metastasis • Stage II: distant metastasis present This simplified system reflects the outstanding prognosis in younger individuals, with more than 98% survival regardless of tumor characteristics. For patients 55 years and older, staging becomes more detailed and incorporates tumor size, lymph node involvement, and extrathyroidal extension. Importantly, the 8th edition refined the definition of extrathyroidal extension so that only gross invasion of strap muscles qualifies for T3b staging, which has downstaged many patients and improved prognostic accuracy. However, staging alone does not fully predict recurrence. That role belongs to the American Thyroid Association (ATA) risk stratification system, which categorizes patients as low, intermediate, or high risk of recurrence. Approximate recurrence rates are: • Low risk: ~1.5% • Intermediate risk: ~5% overall • High risk: ~25% A key innovation in ATA management is dynamic risk stratification, where risk is continuously updated based on response to therapy. Response categories include: • Excellent response: ~4.7% recurrence risk • Indeterminate response: ~17% recurrence • Biochemically incomplete: ~58% recurrence • Structurally incomplete: ~84% recurrence This dynamic approach allows clinicians to de-escalate surveillance and treatment for patients who demonstrate excellent responses over time. At the molecular level, thyroid cancer has a remarkably simple genomic landscape, dominated by mutations activating the MAPK signaling pathway. The most common driver mutation is BRAF V600E, found in about 60% of papillary thyroid cancers. This mutation is associated with classic and tall-cell variants, increased lymph node metastases, and reduced responsiveness to radioactive iodine due to suppression of the sodium-iodide symporter. Another important group includes RAS mutations, seen in follicular thyroid cancers and follicular-variant papillary carcinomas. These tumors often demonstrate vascular invasion but retain better responsiveness to radioactive iodine therapy. Chromosomal rearrangements also play a role. RET/PTC fusions are common in radiation-induced thyroid cancers and pediatric cases, while TERT promoter mutations—particularly when combined with BRAF mutations—are associated with aggressive disease and poor prognosis. Management of differentiated thyroid cancer increasingly emphasizes risk-adapted therapy, particularly regarding radioactive iodine (RAI). RAI can serve three purposes: • Remnant ablation after surgery • Adjuvant therapy to reduce recurrence risk • Treatment of known metastatic disease Modern guidelines recommend avoiding routine RAI in low-risk patients, particularly those with small intrathyroidal papillary cancers ≤2 cm, ...
    続きを読む 一部表示
    29 分